Carlos de Castro
Overview:
Clinical research projects have focused on new and innovative treatments for myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, adult leukemias, and lymphomas
Positions:
Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
M.D. 1985
University of Texas at Dallas
Resident, Medicine
University of Texas at Dallas
Fellow in Hematology-Oncology, Medicine
Duke University
Grants:
EQAPOL - Years 2017 to 2024 - BASE
Administered By
Duke Human Vaccine Institute
Awarded By
National Institutes of Health
Role
Director
Start Date
End Date
Eqapol Opt 1 -2018-2019
Administered By
Duke Human Vaccine Institute
Awarded By
National Institutes of Health
Role
Medical Director
Start Date
End Date
EQAPOL Option 5
Administered By
Duke Human Vaccine Institute
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date
A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study To Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Administered By
Duke Cancer Institute
Awarded By
Apellis Pharmaceuticals, Inc
Role
Principal Investigator
Start Date
End Date
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML)
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Role
Principal Investigator
Start Date
End Date
Publications:
MicroRNA expression in red blood cells from patients with PNH
Authors
Chi, J-TA; Sangokoya, C; De Castro, CM
MLA Citation
Chi, Jen-Tsan Ashley, et al. “MicroRNA expression in red blood cells from patients with PNH.” Blood, vol. 110, no. 11, AMER SOC HEMATOLOGY, 2007, pp. 1073A-1073A.
URI
https://scholars.duke.edu/individual/pub927183
Source
wos
Published In
Blood
Volume
110
Published Date
Start Page
1073A
End Page
1073A
Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.
Authors
Pabon, CM; Li, Z; Hennig, T; de Castro, C; Neff, JL; Horwitz, ME; LeBlanc, TW; Long, GD; Lopez, RD; Sung, AD; Chao, N; Gasparetto, C; Sarantopoulos, S; Adams, DB; Erba, H; Rizzieri, DA
MLA Citation
Pabon, Cindy M., et al. “Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.” Blood Cancer J, vol. 11, no. 5, May 2021, p. 92. Pubmed, doi:10.1038/s41408-021-00481-9.
URI
https://scholars.duke.edu/individual/pub1482850
PMID
33994546
Source
pubmed
Published In
Blood Cancer Journal
Volume
11
Published Date
Start Page
92
DOI
10.1038/s41408-021-00481-9
Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria
Authors
Griffin, M; Hillmen, P; Szer, J; Weitz, IC; Roeth, A; Hoechsmann, B; Panse, J; Usuki, K; Kiladjian, J-J; De Castro, CM; Nishimori, H; Tan, L; Hamdani, M; Deschatelets, P; Francois, C; Grossi, F; Risitano, A; De Latour, RP
MLA Citation
Griffin, Morag, et al. “Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.” British Journal of Haematology, vol. 193, 2021, pp. 63–65.
URI
https://scholars.duke.edu/individual/pub1483488
Source
wos-lite
Published In
British Journal of Haematology
Volume
193
Published Date
Start Page
63
End Page
65
P132 Cost of transfusion dependency among managed care patients with myelodysplastic syndromes
Authors
Frytak, JR; Henk, HJ; de Castro, CM; Halpern, R; Nelson, M
MLA Citation
Frytak, J. R., et al. “P132 Cost of transfusion dependency among managed care patients with myelodysplastic syndromes.” Leukemia Research, vol. 31, Elsevier BV, May 2007, pp. S111–12. Crossref, doi:10.1016/s0145-2126(07)70202-3.
URI
https://scholars.duke.edu/individual/pub927196
Source
crossref
Published In
Leukemia Research
Volume
31
Published Date
Start Page
S111
End Page
S112
DOI
10.1016/s0145-2126(07)70202-3
"Superiority of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria, Regardless of Prior Transfusion Requirement: Analysis at 16-weeks of PEGASUS Phase 3 Randomized Trial"
Authors
De latour, RP; De Castro, CM; Szer, J; Usuki, K; Hillmen, P; Griffin, M; Hamdani, M; Ajayi, T; Nishimori, H; Weitz, IC
MLA Citation
De latour, Regis Peffault, et al. “"Superiority of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria, Regardless of Prior Transfusion Requirement: Analysis at 16-weeks of PEGASUS Phase 3 Randomized Trial".” British Journal of Haematology, vol. 193, 2021, pp. 189–90.
URI
https://scholars.duke.edu/individual/pub1483489
Source
wos-lite
Published In
British Journal of Haematology
Volume
193
Published Date
Start Page
189
End Page
190
Professor of Medicine
Contact:
Box 3961 Med Ctr, Durham, NC 27710
Box 3961, 2400 Pratt St North Pavilion Suite 5000, Durham, NC 27710